![](https://monteverdelaw.com/wp-content/uploads/case-logo/flex-pharma-inc.jpg)
We are investigating the Board of Directors of Flex Pharma, Inc. (NasdaqCM: FLKS) related to the sale of the company to Salarius Pharmaceuticals, LLC. Under the terms of the proposed transaction, FLKS stockholders will own 19.9% of the combined company upon completion of the transaction.